Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Niels. C. Riedemann"'
Autor:
Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group
Publikováno v:
Intensive Care Medicine Experimental, Vol 11, Iss 1, Pp 1-13 (2023)
Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab
Externí odkaz:
https://doaj.org/article/e86ee766afad44129031898eb17d0604
Autor:
Alexander P. J. Vlaar, Endry H. T. Lim, Sanne deBruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, Ren‐Feng Guo, Leo M. A. Heunks, Matthias H. Busch, Pieter vanPaassen, Niels C. Riedemann, Diederik van deBeek
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 854-858 (2022)
Abstract Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX‐1) in patients with severe coronavirus di
Externí odkaz:
https://doaj.org/article/9ac0c341bdd04701b82fba38b9b0a290
Autor:
Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, Leo M A Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H T Lim, Matthijs C Brouwer, Pieter R Tuinman, José F K Saraiva, Gernot Marx, Suzana M Lobo, Rodrigo Boldo, Jesus A Simon-Campos, Alexander D Cornet, Anastasia Grebenyuk, Johannes M Engelbrecht, Murimisi Mukansi, Philippe G Jorens, Robert Zerbib, Simon Rückinger, Korinna Pilz, Renfeng Guo, Diederik van de Beek, Niels C Riedemann, Alexander P.J. Vlaar, Leo M.A. Heunks, Endry H.T. Lim, Matthijs C. Brouwer, Pieter R. Tuinman, José Francisco K. Saraiva, Suzana Lobo, Jesus Simon-Campos, Alexander D. Cornet, Johannes Engelbrecht, Philippe G. Jorens, Niels C. Riedemann, Pierre Bulpa, Fabio S. Taccone, Greet Hermans, Marc Diltoer, Michael Piagnerelli, Nikolaas De Neve, Antonio T. Freire, Felipe D. Pizzol, Anna Karolina Marinho, Victor H. Sato, Clovis Arns da Cunha, Mathilde Neuville, Jean Dellamonica, Djillali Annane, Antoine Roquilly, Jean Luc Diehl, Francis Schneider, Jean Paul Mira, Jean Baptiste Lascarrou, Luc Desmedt, Claire Dupuis, Carole Schwebel, Guillaume Thiéry, Matthias Gründling, Marc Berger, Tobias Welte, Michael Bauer, Ulrich Jaschinski, Klaus Matschke, Roberto Mercado-Longoria, Belinda Gomez Quintana, Jorge Alberto Zamudio-Lerma, Juan Moreno Hoyos Abril, Angel Aleman Marquez, Peter Pickkers, Luuk Otterspoor, Luis Hercilla Vásquez, Carlos Rafael Seas Ramos, Alejandro Peña Villalobos, Gonzalo Gianella Malca, Victoria Chávez, Victor Filimonov, Vladimir Kulabukhov, Pinak Acharya, Sjoerd A.M.E.G. Timmermans, Matthias H. Busch, Floor L.F. van Baarle, Rutger Koning, Liora ter Horst, Nora Chekrouni, Thijs M. van Soest, Marleen A. Slim, Lonneke A. van Vught, Rombout B.E. van Amstel, Sabine E. Olie, Ingeborg E. van Zeggeren, Marcel C.G. van de Poll, Claus Thielert, Dorothee Neukirchen
Publikováno v:
The Lancet Respiratory medicine, 10(12), 1137-1146. ELSEVIER SCI LTD
Lancet respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 12, pp. 1137-1146
The lancet respiratory medicine
PANAMO study group 2022, ' Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial ', Lancet respiratory medicine, vol. 10, no. 12, pp. 1137-1146 . https://doi.org/10.1016/S2213-2600(22)00297-1
lancet. Respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 1137-1146
Lancet respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 12, pp. 1137-1146
The lancet respiratory medicine
PANAMO study group 2022, ' Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial ', Lancet respiratory medicine, vol. 10, no. 12, pp. 1137-1146 . https://doi.org/10.1016/S2213-2600(22)00297-1
lancet. Respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 1137-1146
Contains fulltext : 287661.pdf (Publisher’s version ) (Closed access) BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f8ba6e900c408360d398f60555ae06e
https://cris.maastrichtuniversity.nl/en/publications/bd6096d8-38fc-4032-bed0-e61be7ec1575
https://cris.maastrichtuniversity.nl/en/publications/bd6096d8-38fc-4032-bed0-e61be7ec1575
Autor:
Leo M. A. Heunks, Frank E.H.P. van Baarle, Lieuwe D. J. Bos, Frederique Paulus, Esther B. Bulle, Simon Rueckinger, Marcus J. Schultz, Matthijs C. Brouwer, Pieter van Paassen, Janneke Horn, Martin Witzenrath, Ingeborg E. van Zeggeren, E. Marleen Kemper, W. Joost Wiersinga, Marcel C. G. van de Poll, Sjoerd A.M.E.G. Timmermans, Rutger Koning, Korinna Pilz, Niels C. Riedemann, Alexander P.J. Vlaar, Diederik van de Beek, Iwan C. C. van der Horst, Matthias Busch, Sanne de Bruin, Liora ter Horst, Ren Feng Guo
Publikováno v:
The Lancet Rheumatology, 2(12), e764-e773. Lancet Publishing Group
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
Background Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a3cabed40314643ba9bb8842abe17e
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
Autor:
Alexander P. J. Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, Esther B. Bulle, Frank E.H.P. van Baarle, Marcel C.G. van de Poll, E. Marleen Kemper, Iwan C.C. van der Horst, Marcus J. Schultz, Janneke Horn, Frederique Paulus, Lieuwe D. Bos, W. Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C. Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels. C. Riedemann, Diederik van de Beek
Publikováno v:
SSRN Electronic Journal.
Background: Severe coronavirus disease 2019 (Covid-19) is characterized by inflammation and coagulation in the presence of complement activation. Methods: We conducted an explorative phase 2 randomized, open label first part of an adaptive phase 2/3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca898a56285a84f2c861a83f578da495
https://doi.org/10.2139/ssrn.3658226
https://doi.org/10.2139/ssrn.3658226
Autor:
Peter Recknagel, Falk A Gonnert, Martin Westermann, Sandro Lambeck, Amelie Lupp, Alain Rudiger, Alex Dyson, Jane E Carré, Andreas Kortgen, Christoph Krafft, Jürgen Popp, Christoph Sponholz, Valentin Fuhrmann, Ingrid Hilger, Ralf A Claus, Niels C Riedemann, Reinhard Wetzker, Mervyn Singer, Michael Trauner, Michael Bauer
Publikováno v:
PLoS Medicine, Vol 9, Iss 11, p e1001338 (2012)
BackgroundHepatic dysfunction and jaundice are traditionally viewed as late features of sepsis and portend poor outcomes. We hypothesized that changes in liver function occur early in the onset of sepsis, yet pass undetected by standard laboratory te
Externí odkaz:
https://doaj.org/article/cf339bafd25349caa950811263c7ea3a
Publikováno v:
Critical Care Research and Practice, Vol 2012 (2012)
There is evidence in sepsis, both in rodents and in humans, that activation of the complement system results in excessive production of C5a, which triggers a series of events leading to septic shock, multiorgan failure, and lethality. In rodents foll
Externí odkaz:
https://doaj.org/article/17cbd0610c5e4985b3135826a5804565
Autor:
Frank Bloos, Svea Sachse, Andreas Kortgen, Mathias W Pletz, Marc Lehmann, Eberhard Straube, Niels C Riedemann, Konrad Reinhart, Michael Bauer
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e46003 (2012)
BACKGROUND: Treatment of septic shock relies on appropriate antimicrobial therapy. Current culture based methods deliver final results after days, which may delay potentially lifesaving adjustments in antimicrobial therapy. This study was undertaken
Externí odkaz:
https://doaj.org/article/8e39763cfd0044438478b85ed8cc72c9
Autor:
Marlen Hermann, Jana Ziereisen, Karim Kentouche, Conny Schneider, Renfeng Guo, Maria Habel, Michael Kirschfink, Cyrill Wehling, Niels C. Riedemann
Publikováno v:
Clinical Immunology. 180:25-32
The terminal complement split product C5a has been described as an important mediator in inflammatory diseases. C5a is generated upon cleavage of C5 and earlier research suggests that, besides the known C5 convertases formed upon activation of the co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85dddd0e477cb597e8f1f79a85a70d73
https://doi.org/10.1016/j.clim.2017.03.012
https://doi.org/10.1016/j.clim.2017.03.012
Autor:
Isabella Westermann, Niels C. Riedemann, Daniel Schwarzkopf, Helga Skupin, Michael Fritzenwanger, Christiane S. Hartog, Konrad Reinhart, Ruediger Pfeifer, Otto W. Witte, Albrecht Günther
Publikováno v:
Journal of Critical Care. 30:187-195
Purpose The aim of this study was to create a questionnaire that measures barriers and facilitators of effective end-of-life (EOL) decision making and communication and associated stress as perceived by intensive care unit (ICU) staff. Methods The qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417965b35ef44ad6be3d7698e77c1705
https://doi.org/10.1016/j.jcrc.2014.09.015
https://doi.org/10.1016/j.jcrc.2014.09.015